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ABSTRACT
There is a clinical need for new treatment options for serious Gram-positive infections. Recently
introduced agents such as the newer ﬂuoroquinolones and the ketolide telithromycin have limited use
as they do not cover methicillin-resistant Staphylococcus aureus (MRSA) or glycopeptide-resistant
enterococci (GRE). The clinical use of the streptogramin combination quinupristin/dalfopristin, which
has activity against MRSA and vancomycin-resistant Enterococcus faecium, is limited because
administration is via a slow infusion of a large volume. The oxazolidinone linezolid is active against
MRSA and GRE but resistant organisms and treatment failures have been reported. A number of
compounds currently in development show promise, the new glycopeptides oritavancin, dalbavancin
and the glycolipodepsipeptide ramoplanin, as well as the new tetracyclines tigecycline and BAY73-
7388. However, in some cases, there is concern that resistance may develop quickly to new
compounds that are based on existing antimicrobial agents. Therefore daptomycin, a novel lipopeptide
with a unique mode of action, is of particular interest. Daptomycin is active against MRSA (including
vancomycin-resistant strains) and GRE. Daptomycin displays rapid concentration-dependent killing
and is bactericidal even in the stationary phase of growth. Daptomycin-resistant strains are very
difﬁcult to generate in vitro. A dosage of 4 mg/kg intravenous once a day has been shown to be
efﬁcacious in two evaluator-blinded trials of complicated skin and soft tissue infections with clinical
success rates similar for daptomycin and comparators (vancomycin or penicillinase-resistant
penicillins). With its activity against key Gram-positive pathogens, including resistant strains,
daptomycin has potential as a valuable addition to the available treatment options for serious Gram-
positive infections.
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INTRODUCTION
The need for new antimicrobial agents and
strategies for their use in the treatment of serious
Gram-positive infections is evident. The develop-
ment of antimicrobial resistance among Gram-
positive pathogens that cause serious infections
and the resultant treatment limitations have been
described previously in this supplement [1,2].
Antimicrobial resistance can be categorised in a
number of ways.
• Microbiological resistance is deﬁned as the
presence of a resistance mechanism, demon-
strated either phenotypically or genotypically
and is unrelated to clinical outcome.
• Clinical resistance is expressed when the infec-
tion is unlikely to respond even to a maximal
dose of a given antimicrobial agent.
• Cross-resistance is deﬁned as resistance to a
closely related group/class of antimicrobial
agents sharing a common mechanism(s) of
resistance. For example, ciproﬂoxacin-resistant
isolates which are also levoﬂoxacin resistant or
non-susceptible.
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• Parallel or co-resistance occurs when resistance
is exhibited to unrelated antimicrobial agents,
for example, resistance to methicillin and gen-
tamicin in Staphylococcus aureus.
This article will summarise recently introduced
agents and give examples of agents currently in
development, covering both new and existing
mechanisms of action. Focus will be given to
daptomycin, a novel lipopeptide antimicrobial
agent, which has recently received approval in the
USA for the treatment of complicated skin and
soft tissue infections (SSTIs).
RECENTLY INTRODUCED AGENTS
Recently introduced antimicrobial agents in-
clude the newer quinolones levoﬂoxacin, mox-
iﬂoxacin and gatiﬂoxacin. However, these
agents are of limited use in the treatment of
serious Gram-positive infections, as they do not
cover methicillin-resistant S. aureus (MRSA),
since most strains are also ﬂuoroquinolone
resistant. In addition, their utility may be
affected by cross-resistance to earlier ﬂuoroqu-
inolones such as ciproﬂoxacin. The streptogram-
in combination quinupristin/dalfopristin has
recently become available. It has activity against
S. aureus and Enterococcus faecium but it is
difﬁcult to administer (requiring a slow infusion
of a large volume and a central line) and has no
activity against Enterococcus faecalis [3]. Other
recently introduced antimicrobial agents are
telithromycin and linezolid. Telithromycin, a
ketolide, has activity against multi-drug resist-
ant pneumococci [4] but will be of limited use
against serious infections due to the lack of an
intravenous form. Linezolid is a synthetic anti-
microbial agent belonging to a new class, the
oxazolidinones, and it is available for intraven-
ous or oral administration with 100% bioavail-
ability. It is effective in the treatment of serious
Gram-positive infections, such as those caused
by vancomycin-resistant E. faecium, nosocomial
pneumonia caused by S. aureus (including
MRSA) or penicillin-susceptible Streptococcus
pneumoniae and complicated skin and soft tissue
infections caused by S. aureus, Streptococcus
pyogenes or Streptococcus agalactiae [http://
www.zyvox.com]. Development of resistant
organisms has so far been infrequent; however,
resistant organisms and clinical failures have
been reported [5–8].
FUTURE COMPOUNDS: EXISTING
MECHANISMS OF ACTION
A summary of compounds currently in develop-
ment that belong to existing classes of antimicro-
bial agents is presented in Table 1. In the
glycopeptide/glycolipodepsipeptide class are
three promising compounds: oritavancin
(LY-333328), dalbavancin (BI-397) and ramopla-
nin. A Phase III trial of SSTIs has been completed
for oritavancin; dalbavancin had completed Phase
II for SSTIs and ramoplanin, which has fast track
status from the FDA, is currently being studied
for the treatment of Clostridium difﬁcile-associated
diarrhoea (Phase II). Additionally presented in
Table 1. Examples of antimicrobial compounds currently in development
Class Compound Sponsor
Glycopeptides/
Glycolipodepsipeptides
Oritavancin (LY-333328) InterMune
Dalbavancin (BI-397) Vicuron Pharmaceuticals
Ramoplanin Oscient Pharmaceuticals
Quinolones Garenoxacin (T 3811) Schering Plough and Toyama Chemical Co
Sitaﬂoxacin (DU-6859a) Daiichi Pharmaceutical Corp
DW 286a Dong Wha Pharmaceutical Ind. Co. Ltd
Glycylcyclines Tigecycline (GAR 936) Wyeth Research
Aminomethylcycline BAY 73-6944/BAY 73-7388 (PTK 0796) Paratek Pharmaceuticals and
Bayer Healthcare Pharmaceuticals
Dihydrofolate reductase
inhibitors
Iclaprim (AR-100/Ro 48-2622) Arpida Ltd
b-Lactams BAL-5788 (Ro 65-5788)
[Active compound BAL-9141]
Basilea Pharmaceutical AG
Oxazolidinones Ranbezolid (RBX 7644) Ranbaxy Research Laboratories
DA 7867 Dona-A Pharm
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Table 1 are some examples of quinolones, glyc-
ylcyclines, dihydrofolate reductase inhibitors,
b-lactams and oxazolidinones that are currently
in development.
The development of new antimicrobial agents
that belong to existing classes can raise problems
in terms of cross-resistance. For example, in the
ﬂuoroquinolone class, among oﬂoxacin-resistant
isolates of MRSA, the MIC of sitaﬂoxacin is higher
when compared with oﬂoxacin-susceptible iso-
lates (Table 2). The same is true for sitaﬂoxacin
against ciproﬂoxacin-resistant isolates of S. pneu-
moniae (Table 2). Some compounds have been
developed in order to circumvent the mechanisms
of cross-resistance. For example, the glycylcy-
clines and the aminomethylcyclines were devel-
oped in order to avoid the resistance mechanisms
that had developed to the tetracyclines. Tigecy-
cline is the glycylcycline that is furthest through
the development process, and Paratek and Bayer
Pharmaceuticals have a collaborative agreement
to pursue the development of the aminomethyl-
cycline PTK 0796 (BAY 73-7388).
A further example of a possible future com-
pound is iclaprim, a dihydrofolate reductase inhib-
itor, which has just completed Phase II trials for
SSTIs.However, cross-resistancemaybe aproblem
ashigherMIC50 andMIC90 values for iclaprimhave
been reported for MRSAwith reduced susceptibil-
ity to co-trimoxazole/trimethoprim (co-trimoxaz-
ole/trimethoprim-susceptible MIC50 0.06 mg/L,
MIC90 0.5 mg/L; co-trimoxazole/trimethoprim-
resistant MIC50 8.0 mg/L, MIC90 32 mg/L) [9].
ACTIVITY AGAINST VANCOMYCIN-
RESISTANT MRSA
As discussed previously in this supplement,
three isolates of vancomycin-resistant S. aureus
(VRSA) have been identiﬁed in the USA recently
[10–12]. The activity (MIC) of selected com-
pounds against the ﬁrst two of these isolates is
given in Table 3. Both isolates were susceptible
to linezolid (MIC £4 mg/L) [13]. Examining the
MIC of the newer compounds, the MIC of
oritavancin against the Detroit VRSA isolate
was above the oritavancin MIC that would be
expected for a vancomycin-susceptible isolate,
but against the Hershey isolate the MIC of
Table 2. Activity (MIC50, MIC90 and range in mg/L) of ﬂuoroquinolones against ﬂuoroquinolone-susceptible and
ﬂuoroquinolone-resistant MRSA and Streptococcus pneumoniae
Fluoroquinolone
MRSA S. pneumoniae
Oﬂoxacin susceptible
(n ¼ 24)
Oﬂoxacin resistant
(n ¼ 25)
Ciproﬂoxacin
susceptible (n ¼ 17)a
Ciproﬂoxacin
resistant (n ¼ 5)b
MIC50 MIC90
MIC
range MIC50 MIC90
MIC
range MIC50 MIC90
MIC
range MIC50 MIC90
MIC
range
Garenoxacin 0.03 0.03 0.008–0.06 2 8 0.25–64 0.12 0.12 0.06–0.12 – – 0.5–2
Moxiﬂoxacin 0.12 0.12 0.03–0.25 4 8 1–64 0.25 0.5 0.25–0.5 – – 2–4
Sitaﬂoxacin 0.03 0.06 0.008–0.06 1 4 0.25–32 0.06 0.12 0.06–0.25 – – 0.25–1
DK-507K 0.03 0.06 0.015–0.06 1 4 0.25–32 0.12 0.12 0.06–0.12 – – 0.25–1
Adapted from reference [26].
MIC50, minimum inhibitory concentration as which 50% of isolates are inhibited; MIC90, minimum inhibitory
concentration at which 90% of isolates are inhibited.
aPenicillin non-susceptible isolates.
bMIC50 and MIC90 not presented as <10 isolates.
Table 3. Activity (MIC) of selected antibacterial agents
against vancomycin-resistant and vancomycin-susceptible
Staphylococcus aureus (VRSA and VSSA, respectively)
Antibacterial
agent
MIC (mg/L)
Detroit
(MI) USAa
Hershey
(PA) USAb VSSA
Vancomycin 1024 32 0.5–2
Linezolid 2 1 1–4
Teicoplanin n.d. 4 <0.25–4
Dalbavancin n.d. 0.5 0.06–1
Oritavancin 4 0.25 0.25–2
Ramoplanin n.d. 0.125 n.d.
Daptomycin 1 0.5 0.12–1
MIC, minimum inhibitory concentration; VSSA, vancomy-
cin-susceptible Staphylococcus aureus; n.d., not determined.
aData from reference [10].
bData from reference [11].
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oritavancin was at the bottom of the expected
MIC range for a vancomycin-susceptible isolate.
This variability suggests caution with respect to
reliance upon the efﬁcacy of these new glyco-
peptides against vancomycin-resistant organ-
isms. It is interesting to note that the MIC of
the novel lipopeptide daptomycin and of dalb-
avancin were similar for vancomycin-susceptible
and vancomycin-resistant MRSA.
DAPTOMYCIN
Daptomycin is a novel lipopeptide with a unique
mode of action. The mechanism of action is not
completely understood. Daptomycin is known to
bind to the cytoplasmic membrane via a calcium-
dependent insertion of its lipid tail; this results in
efﬂux of potassium, leading to cell death due to
the widespread dysfunction of macromolecular
synthesis [14]. Importantly, this mode of action
differentiates daptomycin from compounds such
as the b-lactams, as it is not dependent on cell
lysis [14].
In vitro daptomycin has been shown to be
synergistic with arbekacin against glycopeptide-
intermediate MRSA (GISA) [15] and with
rifampicin and ampicillin against high-level
vancomycin-resistant enterococci [16], although
the clinical importance of this synergy has yet to
be demonstrated. Daptomycin has a post-antibi-
otic effect of 1–6 h [17,18].
Daptomycin displays rapid concentration-
dependent bactericidal activity (Fig. 1) [18],
and importantly, its bactericidal activity is
maintained in the stationary phase (Fig. 2).
Comparing the minimum bactericidal concen-
tration (MBC) with the MIC, daptomycin is
bactericidal at concentrations very close to the
MIC (Table 4).
Resistance to daptomycin is difﬁcult to gener-
ate. In the study by Silverman et al. [19] no
spontaneously daptomycin-resistant isolates were
obtained, yielding resistance rates of <10)10 for
S. aureus (n ¼ 4 strains) and <10)9 for Staphylo-
coccus epidermidis (n ¼ 4), E. faecalis (n ¼ 4),
E. faecium (n ¼ 2) and Streptococcus pneumoniae
(n ¼ 2).
The pharmacokinetics of daptomycin are rel-
atively simple (Table 5). Daptomycin has a long
half-life, making it suitable for once a day
dosing. It is primarily excreted unchanged by
the kidneys; in the study by Woodworth et al.
[20] c. 83% of a dose of 1 mg/kg was account-
able from urinary and faecal recovery. The
metabolites were not identiﬁed and had no
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Fig. 1. In-vitro bactericidal activity of daptomycin, linezo-
lid and vancomycin against methicillin-resistant Staphylo-
coccus aureus. Reproduced from reference [29] with
permission.
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
0 12 24 36 48 60 72
Time (hours)
CF
U/
g 
(lo
g 1
0)
Control
Daptomycin
Nafcillin
Linezolid
Vancomycin
Fig. 2. Bactericidal activity of a range of antimicrobial
agents against methicillin-susceptible Staphylococcus aureus
in stationary phase. Adapted from reference [29].
Table 4. In-vitro activity of daptomycin
Organism n
Daptomycin
MIC range (mg/L) MBC (mg/L)
Methicillin-resistant
S. aureus
50 0.06–0.5 0.06–1.0
Methicillin-resistant
S. epidermidis
25 0.12–2.0 0.06–2.0
E. faecalisa 25 0.25–4.0 0.5–8.0
E. faeciuma 25 0.5–1.0 0.5–4.0
VISA 3 0.5–1.0 1.0
aincluding vancomycin-resistant enterococci.
MIC, minimum inhibitory concentration; MBC, minimal
bactericidal concentration.
Adapted from reference [27].
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antimicrobial activity [20]. The peak concentra-
tion/MIC ratio and 24-h area under the curve
(AUC)/MIC ratio are the pharmacokinetic and
pharmacodynamic parameters that best correlate
with in-vivo efﬁcacy against standard strains of
S. aureus and S. pneumoniae [21].
At a dosage for daptomycin of 4 mg/kg once
a day as an intravenous infusion, no adjustment
is required for hepatic dysfunction [22]. In cases
of renal insufﬁciency (clearance <30 mL/min)
and the use of haemodialysis or continuous
ambulatory peritoneal dialysis (CAPD), 4 mg/
kg should be administered post dialysis and
every 48 h. Approximately 15% of the dose is
removed via 4 h of haemodialysis [http://
www.cubicin.com].
Two randomised, evaluator-blinded trials of
complicated skin and soft tissue infections have
been carried out to date [23]. Each contained
c. 500 patients; study 9901 involved patients in
South Africa, Europe, Australia and Israel and
study 9801 covered the USA and South Africa.
Patients were randomised to daptomycin or a
comparator for 7–14 days (daptomycin 4 mg/kg
IV q24 h or vancomycin 1 g IV q12 h or oxacil-
lin class 4–12 g IV per day). The age range of
the patients was 18–85 years. The incidence of
pathogen isolation is given in Table 6. The
clinical success rates were similar for those
treated with daptomycin and those treated with
a comparator (Table 7). In addition, the success
rate by pathogen and by site were also similar
for daptomycin and the comparators (Tables 8
and 9). Although the MICs of pathogens isola-
ted from patients involved in the clinical trials
have not been published, Arbeit et al. [23] stated
that there was no trend towards increased MICs
among isolates cultured from patients treated
with daptomycin, including those who had
treatment failure.
FUTURE COMPOUNDS: NEW
MECHANISMS OF ACTION
In addition to daptomycin, there are a number
of interesting compounds currently in develop-
ment that have new mechanisms of action.
Table 6. Incidence of pathogen isolation in complicated
skin and soft tissue daptomycin trials 9901 and 9801
(population: all intent to treat patients with a Gram-
positive infection)
Baseline
Gram-positive
pathogens
Daptomycin
(n ¼ 428)
Comparatora
(n ¼ 471)
Staphylococcus aureus 305 (71.3%) 323 (68.6%)
Streptococcus pyogenes 92 (21.5%) 103 (21.9%)
Streptococcus agalactiae 30 (7.0%) 41 (8.7%)
Enterococcus faecalis 45 (10.5%) 61 (13.0%)
Adapted from reference [23].
aComparators were penicillinase-resistant semi-synthetic
penicillins (cloxacillin, ﬂucloxacillin, oxacillin or nafcillin)
or vancomycin.
Table 7. Clinical success rates of complicated skin and soft tissue daptomycin trials 9901 and 9801
Daptomycin Comparatora
95% CIbNo. of patients Success rate (%) No. of patients Success rate (%)
Intent-to-treat 534 71.5 558 71.1 )5.8, 5.0
Clinically evaluable 446 83.4 456 84.2 )4.0, 5.6
Microbiologically evaluable 365 84.7 396 85.9 )3.8, 6.3
Adapted from reference [23].
aComparators were penicillinase-resistant semi-synthetic penicillins (cloxacillin, ﬂucloxacillin, oxacillin or nafcillin) or
vancomycin.
bTarget for trial was 95% CI ± 10%.
Table 5. Pharmacokinetics of daptomycin in healthy
human subjects
Parameter Value
Cmax (after dose of 4 mg/kg) 57.8 mg/L
Half-life 8–9 h
Protein binding 92%
Data from reference [28].
Cmax, maximal concentration after dosing.
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Examples of novel compounds currently under
investigation are as follows:
• Inhibitors of peptide deformylase (a metalloen-
zyme essential for bacterial growth) are cur-
rently under investigation by Oscient
Pharmaceuticals (BB-83698) and by Vicuron
and Novartis in partnership (VRC4887/NVP-
PDF386/VRC-4307/PDF-713).
• Riburamycins, which are simpliﬁed analogues of
liposidomycins, have been shown to strongly
inhibit MraY, an essential enzyme of the pepti-
doglycanpathway [24]. The riburamycinRU75411
is under investigation by Sanoﬁ-Aventis.
• 6-Anilinouracil is an inhibitor of DNA polym-
erase III (pol III), which is essential for the
replication of the host chromosome [25]. Two
compounds (MBX 500 and MBX 037) that target
DNA polymerase are under development by
Microbiotix.
CONCLUSIONS
With the growth in the prevalence of pathogens
such as MRSA and GRE and the emergence of
GISA and glycopeptide-resistant S. aureus, treat-
ment options are becoming increasingly limited
for serious Gram-positive infections. There are a
number of promising compounds in develop-
ment. However, there is concern that resistance
may develop quickly to compounds that are
based on existing antimicrobial classes. There-
fore, new antimicrobial agents with new mech-
anisms of action are particularly important.
Daptomycin is the ﬁrst of the novel class of
antimicrobial agents, the lipopeptides, to reach
clinical development in Europe (approved for
SSTIs in the USA). With its novel mode of
action and activity against MRSA (including
glycopeptide-resistant strains) and GRE it would
make an important addition to the current panel
of available antimicrobial agents.
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